Feedback / Questions
taladegib (ENV 101) - Endeavor BioMed
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
(Businesswire)
Sep 10, 2025
P2a data
•
Idiopathic Pulmonary Fibrosis
https://www.businesswire.com/news/home/20250910067032/en/Endeavor-BioMedicines-to-Present-Results-from-Phase-2a-Trial-of-Taladegib-ENV-101-in-an-ALERT-Session-at-European-Respiratory-Society-ERS-Congress-2025
Sep 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next